Research Article
Expression and Clinical Significance of ILF2 in Gastric Cancer
Table 2
Univariate and multivariate Cox regression analyses for OS and DFS of GC patients.
| Variables | OS | DFS | RR (95% CI) | value | RR (95% CI) | value |
| Univariate analysis | | | | | Gender (male versus female) | 1.856 (0.976–3.529) | 0.059 | 1.579 (0.884–2822) | 0.123 | Age (years) (>60 versus ≤60) | 1.799 (0.944–3.429) | 0.074 | 1.701 (0.948–3.050) | 0.075 | Location (cardia versus body/antrum) | 1.095 (0.589–2.035) | 0.774 | 0.794 (0.448–1.406) | 0.429 | Size (cm) (>5 versus ≤5) | 1.073 (0.560–2.056) | 0.831 | 1.344 (0.748–2.416) | 0.323 | Histological differentiation (well/moderate versus poor/not) | 2.403 (1.173–4.926) | 0.017 | 2.040 (1.089–3.823) | 0.026 | Depth of invasion (T1/T2 versus T3/T4) | 3.135 (1.311–7.495) | 0.010 | 2.741 (1.319–5.695) | 0.007 | Lymph node metastasis (no versus yes) | 1.698 (0.865–3.257) | 0.111 | 1.578 (0.878–2.837) | 0.128 | TNM stage (I/II versus III/IV) | 4.727 (2.218–10.074) | <0.001 | 2.897 (1.565–5.365) | 0.001 | ILF2 expression (high versus low) | 4.496 (2.045–9.883) | <0.001 | 3.251 (1.699–6.224) | <0.001 | CA19-9 (positive versus negative) | 2.254 (1.191–4.264) | 0.012 | 2.223 (1.219–4.054) | 0.009 | CA125 (positive versus negative) | 2.677 (1.399–5.122) | 0.003 | 2.340 (1.268–4.319) | 0.007 | CEA (positive versus negative) | 2.133 (1.117–3.995) | 0.021 | 2.103 (1.105–3.669) | 0.022 | Multivariate analysis | | | | | TNM stage (I/II versus III/IV) | 3.462 (1.451–8.260) | 0.005 | — | — | ILF2 expression (low versus high) | 2.996 (1.173–7.654) | 0.022 | 3.464 (1.727–6.947) | <0.001 | Depth of invasion (T1/T2 versus T3/T4) | 3.849 (1.452–10.206) | 0.007 | 3.669 (1.613–8.343) | 0.002 | CA19-9 (positive versus negative) | 2.911 (1.414–5.994) | 0.004 | 3.210 (1.538–6.701) | 0.002 | CA125 (positive versus negative) | 3.632 (1.695–7.786) | 0.001 | 2.391 (1.193–4.791) | 0.014 |
|
|
95% CI: 95% confidence interval; RR: relative risk; TNM: tumor node metastasis; .
|